Bristol-Myers Squibb (BMY)

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.

Company Overview

With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.

Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing.

Bristol-Myers Squibb competes with other major pharmaceutical companies including Merck (NYSE:MRK), Pfizer (NYSE:PFE), Novartis (NYSE:NVS), AstraZeneca (NASDAQ:AZN), and Roche (OTCQX:RHHBY), particularly in oncology and immunology therapeutic areas.

Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.

With $48.03 billion in revenue over the past 12 months, Bristol-Myers Squibb boasts impressive economies of scale. It may not be as large as heavyweights such as UnitedHealth Group and The Cigna Group from a topline perspective, but its heft is still an important advantage in a healthcare industry that is heavily regulated, complex, and resource-intensive.

A company’s long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Unfortunately, Bristol-Myers Squibb’s 4% annualized revenue growth over the last five years was mediocre. This was below our standard for the healthcare sector and is a rough starting point for our analysis.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Bristol-Myers Squibb’s annualized revenue growth of 3.4% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak.

We can better understand the company’s revenue dynamics by analyzing its most important segment, Growth Portfolio. Over the last two years, Bristol-Myers Squibb’s Growth Portfolio revenue averaged 17.1% year-on-year growth. This segment has outperformed its total sales during the same period, lifting the company’s performance.

This quarter, Bristol-Myers Squibb reported modest year-on-year revenue growth of 2.8% but beat Wall Street’s estimates by 3.4%.

Looking ahead, sell-side analysts expect revenue to decline by 6.9% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and suggests its products and services will see some demand headwinds.

Bristol-Myers Squibb has done a decent job managing its cost base over the last five years. The company has produced an average operating margin of 10%, higher than the broader healthcare sector.

Analyzing the trend in its profitability, Bristol-Myers Squibb’s operating margin rose by 9.7 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company’s trajectory is intact as its margin has also increased by 2.1 percentage points on a two-year basis.

In Q3, Bristol-Myers Squibb generated an operating margin profit margin of 25.5%, up 9.4 percentage points year on year. This increase was a welcome development and shows it was more efficient.

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Bristol-Myers Squibb’s EPS grew at an unimpressive 1.1% compounded annual growth rate over the last five years, lower than its 4% annualized revenue growth. We can see the difference stemmed from higher interest expenses or taxes as the company actually improved its operating margin and repurchased its shares during this time.

In Q3, Bristol-Myers Squibb reported adjusted EPS of $1.63, down from $1.80 in the same quarter last year. Despite falling year on year, this print beat analysts’ estimates by 7.6%. Over the next 12 months, Wall Street expects Bristol-Myers Squibb’s full-year EPS of $6.56 to shrink by 4.7%.

Although earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.

Bristol-Myers Squibb has shown terrific cash profitability, enabling it to reinvest, return capital to investors, and stay ahead of the competition while maintaining an ample cushion. The company’s free cash flow margin was among the best in the healthcare sector, averaging 28.3% over the last five years.

Taking a step back, we can see that Bristol-Myers Squibb’s margin dropped by 3.2 percentage points during that time. If its declines continue, it could signal increasing investment needs and capital intensity.

EPS and free cash flow tell us whether a company was profitable while growing its revenue. But was it capital-efficient? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).

Bristol-Myers Squibb historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 3.3%, lower than the typical cost of capital (how much it costs to raise money) for healthcare companies.

We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Over the last few years, Bristol-Myers Squibb’s ROIC has unfortunately decreased. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.

Bristol-Myers Squibb reported $16.5 billion of cash and $48.98 billion of debt on its balance sheet in the most recent quarter. As investors in high-quality companies, we primarily focus on two things: 1) that a company’s debt level isn’t too high and 2) that its interest payments are not excessively burdening the business.

With $20.81 billion of EBITDA over the last 12 months, we view Bristol-Myers Squibb’s 1.6× net-debt-to-EBITDA ratio as safe. We also see its $1.08 billion of annual interest expenses as appropriate. The company’s profits give it plenty of breathing room, allowing it to continue investing in growth initiatives.

We enjoyed seeing Bristol-Myers Squibb beat analysts’ revenue expectations this quarter. We were also happy its full-year EPS guidance outperformed Wall Street’s estimates. Overall, we think this was a decent quarter with some key metrics above expectations. The stock remained flat at $43 immediately after reporting.

Updated: December 4, 2025 at 11:02 PM EST

Before investing in or passing on Bristol-Myers Squibb, we urge you to understand the company’s business quality (or lack thereof), valuation, and the latest quarterly results - in that order.

Bristol-Myers Squibb’s business quality ultimately falls short of our standards. To kick things off, its revenue growth was mediocre over the last five years, and analysts expect its demand to deteriorate over the next 12 months. And while its powerful free cash flow generation enables it to stay ahead of the competition through consistent reinvestment of profits, the downside is its diminishing returns show management's prior bets haven't worked out. On top of that, its declining adjusted operating margin shows the business has become less efficient.

Bristol-Myers Squibb’s P/E ratio based on the next 12 months is 8.2x. While this valuation is optically cheap, the potential downside is big given its shaky fundamentals. We're fairly confident there are better stocks to buy right now.

Wall Street analysts have a consensus one-year price target of $53.41 on the company (compared to the current share price of $52.05).